tbuckley/cabot-search huggingface dataset:
Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association
Authors: Kristin E. Sandau, Marjorie Funk, Andrew Auerbach, Gregory W. Barsness, Kay Blum, Maria Cvach, Rachel Lampert, Jeanine L. May, George M. McDaniel, Marco V. Perez, Sue Sendelbach, Claire E. Sommargren, Paul J. Wang
Journal: Circulation (2017)

Background and Purpose: This scientific statement provides an interprofessional, comprehensive review of evidence and recommendations for indications, duration, and implementation of continuous electro cardiographic monitoring of hospitalized patients. Since the original practice standards were published in 2004, new issues have emerged that need to be addressed: overuse of arrhythmia monitoring among a variety of patient populations, appropriate use of ischemia and QT-interval monitoring among select populations, alarm management, and documentation in electronic health records. Methods: Authors were commissioned by the American Heart Association and included experts from general cardiology, electrophysiology (adult and pediatric), and interventional cardiology, as well as a hospitalist and experts in alarm management. Strict adherence to the American Heart Association conflict of interest policy was maintained throughout the consensus process. Authors were assigned topics relevant to their areas of expertise, reviewed the literature with an emphasis on publications since the prior practice standards, and drafted recommendations on indications and duration for electrocardiographic monitoring in accordance with the American Heart Association Level of Evidence grading algorithm that was in place at the time of commissioning. Results: The comprehensive document is grouped into 5 sections: (1) Overview of Arrhythmia, Ischemia, and QTc Monitoring; (2) Recommendations for Indication and Duration of Electrocardiographic Monitoring presented by patient population; (3) Organizational Aspects: Alarm Management, Education of Staff, and Documentation; (4) Implementation of Practice Standards; and (5) Call for Research. Conclusions: Many of the recommendations are based on limited data, so authors conclude with specific questions for further research.
An integrated bacterial system for the discovery of chemical rescuers of disease-associated protein misfolding
Authors: Ilias Matis, Dafni Chrysanthi Delivoria, Barbara Mavroidi, Nikoletta Papaevgeniou, Stefania Panoutsou, Stamatia Bellou, Konstantinos D. Papavasileiou, Zacharoula I. Linardaki, Alexandra V. Stavropoulou, Kostas Vekrellis, Nikos Boukos, Fragiskos N. Kolisis, Efstathios S. Gonos, Marigoula Margarity, Manthos G. Papadopoulos, Spiros Efthimiopoulos, Maria Pelecanou, Niki Chondrogianni, Georgios Skretas
Journal: Nature Biomedical Engineering (2017)
Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
Authors: Claud Grigg, Brian D. Reuland, Adrian G. Sacher, Randy Yeh, Naiyer A. Rizvi, Catherine A. Shu
Journal: Journal of Clinical Oncology (2017)

9082 Background: Objective response rates (ORR) to chemotherapy beyond the first-line for advanced NSCLC are low (5-10%). Pre-clinical studies suggest that some chemotherapies may act, in part, through immune mediated mechanisms. Additionally, results from phase I/II studies of chemotherapy combined with immune checkpoint inhibitors (ICIs) suggest high response rates ( &gt; 50%) and potential synergy. It is unknown whether chemotherapy is more efficacious when given after ICIs. Methods: We reviewed demographics, imaging, treatment history, and clinical course for all patients at our institution with a diagnosis of metastatic NSCLC who received at least one dose of nivolumab, pembrolizumab, atezolizumab, or durvalumab prior to December 8, 2016. Patients who received any subsequent chemotherapy were included for analysis. Objective response was determined by RECIST v1.1, and date of progression was determined radiographically or clinically (treatment discontinuation with documented clinical deterioration). Results: 145 patients received at least one dose of any ICI, and 38 patients received subsequent chemotherapy. The median age was 68 years (range 44-88). Six chemotherapy-naïve patients received carboplatin + pemetrexed +/- bevacizumab. There were 3 partial responses (PR) including one exceptional response that is ongoing after 2 years. Among 32 chemotherapy non-naïve patients, the median number of prior chemotherapy regimens was 2 (range 1-6). Post-ICI chemotherapy included docetaxel + ramucirumab (n = 12), vinorelbine (n = 7), gemcitabine-based chemotherapy (n = 6), carboplatin doublets (n = 4), pemetrexed + bevacizumab (n = 2), and paclitaxel (n = 1). Six patients had documented poor performance status and died within 1 month of starting treatment. The ORR was 25% (1CR, 7PR), median time to progression was 116 days, and 9 patients (28%) experienced stable disease (SD) or better lasting &gt; 150 days. Exceptional responses occurred across regimens. Nine patients received a further line of chemotherapy, with 3 ongoing PR or SD lasting &gt; 100 days. Conclusions: For NSCLC, chemotherapy response rates may be higher when administered after an ICI.
Cell-free circulating DNA as independent prognostic markers in metastatic breast cancer
Authors: J. Cheng, H. Surowy, M. Wallwiener, T. Holland-Letz, K. Cuk, S. Schott, A. Trumpp, K. Pantel, C. Sohn, A. Schneeweiss, B. Burwinkel
Journal: Annals of Oncology (2017)
Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status
Authors: A. Jayaram, K. Nowakowska, J. Mateo, T. Hernandez, S. Kumar, B. Fulton, D. Nava Rodrigues, R. Riisnaes, A. Zukiwski, S. Proniuk, A.S. Bexon, J. Bisaha, D. Bianchini, Z. Zafeiriou, R.P. Lopez, N. Tunariu, S. Pacey, R. Jones, J. Sebastian de Bono, G. Attard
Journal: Annals of Oncology (2017)
GW28-e0990 Association between use of lipid-lowering agents and the risk of the macular degeneration in the participants with dyslipidemia: a cross-sectional study
Authors: Qiuju Deng, Jing Liu, Wei Wang, Miao Wang, Yue Ql, Jiayi Sun, Jun Liu, Wuxiang Xie, Fan Zhao, Yan Li, Dong Zhao
Journal: Journal of the American College of Cardiology (2017)
Randomized phase ii trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer
Authors: J-M. Sun, M-J. Ahn, J.S. Ahn, H.K. Kim, Y.C. Ahn, J.I. Zo, Y.M. Shim, K. Park
Journal: Annals of Oncology (2017)
Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data
Authors: David A Jolliffe, Lauren Greenberg, Richard L Hooper, Christopher J Griffiths, Carlos A Camargo, Conor P Kerley, Megan E Jensen, David Mauger, Iwona Stelmach, Mitsuyoshi Urashima, Adrian R Martineau
Journal: The Lancet Respiratory Medicine (2017)
Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15
Authors: R. Corre, R. Gervais, L. Tassy, F. Guisier, R. Lamy, G. Fraboulet, L. Greillier, H. Doubre, C. chouaid, J.B. Auliac
Journal: Annals of Oncology (2017)
Clinical factors associated with mutation burden in non-small cell lung cancer
Authors: A. Ono, M. Serizawa, K. Omae, M. Isaka, H. Kojima, S. Takahashi, K. Nakashima, S. Omori, K. Wakuda, H. Kenmotsu, T. Naito, H. Murakami, K. Urakami, Y. Ohde, T. Nakajima, M. Kusuhara, K. Yamaguchi, T. Takahashi
Journal: Annals of Oncology (2017)
Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer
Authors: E.M. McCrea, P.A. Huang, E.M. Harris, J.D. Strope, T.M. Sissung, D.K. Price, C.H. Chau, W.D. Figg
Journal: Annals of Oncology (2017)
Travel &amp; Routine Immunizations: A Practical Guide for the Medical Office
Authors: James Nora, Bradley N. Doebbeling
Journal: Annals of Internal Medicine (2002)

Medical Writings: Book Notes5 November 2002Travel & Routine Immunizations: A Practical Guide for the Medical OfficeJames Nora, MD and Bradley N. Doebbeling, MD, MScJames Nora, MDUniversity of Iowa College of MedicineUniversity of Iowa Colleges of Medicine and Public Health, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa.Search for more papers by this author and Bradley N. Doebbeling, MD, MScUniversity of Iowa College of MedicineUniversity of Iowa Colleges of Medicine and Public Health, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-9-200211050-00038 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail 2001 edition. Thompson RF. 258 pages. Milwaukee: Shoreland; 2001. $25.00. ISSN 1079-9664. Order at www.shoreland.com.Field of medicine: Infectious diseases, travel medicine, and adult and pediatric primary care.Format: Softcover book.Audience: Providers who administer vaccines in a travel medicine clinic or as routine primary care of adults or children.Purpose: To provide a practical office reference to address questions about the administration of all vaccines commercially available in the United States.Content: The book is divided into six sections. Section 2 covers immunizations that are currently available, with specific information on indications, dosing, storage, administration, side effects, and contraindications. ... Author, Article, and Disclosure InformationAffiliations: University of Iowa College of MedicineUniversity of Iowa Colleges of Medicine and Public Health, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2002Volume 137, Issue 9Page: 782KeywordsChildrenHealth information technologyInfectious diseasesPatientsPregnancyPrevention, policy, and public healthProphylaxisSoftware toolsVaccinesVeteran care ePublished: 5 November 2002 Issue Published: 5 November 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Non-communicable disease risk factors: a call for primary care clinicians to act and to refer. Brief intervention, not silent abdication.
Authors: Anna L Beale, Alessandro R Demaio
Journal: British Journal of Sports Medicine (2017)

In a single century, preventable chronic disease has gone from marginal killer to major cause of global mortality.

Non-communicable diseases (NCDs), including cardiovascular disease, cancers, chronic respiratory diseases and diabetes, are the leading causes of death and morbidity globally.1 Ischaemic heart disease and stroke alone accounted for 15 of the 56.4 million deaths worldwide in 2015, and together NCDs represented 70% of total mortality.2 The main drivers across all four NCDs are shared and include tobacco use, unhealthy diet, physical inactivity and the harmful use of alcohol;1 risk factors that are uniformly preventable and for which there are clear policy and clinical practice solutions.

A modest 10% reduction in physical inactivity worldwide could lead to 533 000 fewer deaths annually.3 There is strong evidence for the role of physical inactivity in driving at least 9% of premature mortality attributable among NCDs. Similarly, obesity and poor diet are each responsible for approximately 4% of the global burden of disease, accounting for more than …
Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing.
Authors: Wen-xian Wang, Chunwei Xu, Meiyu Fang, You-cai Zhu, Yan-ping Chen, Yu Chen, Xing-hui Liao, Wu Zhuang, Gen Lin, Xiao-hui Chen, Yun-jian Huang, Hai-peng Xu, Kai-qi Du, Yan-Fang Guan, Xin Yi, Gang Chen, Tangfeng Lv, Yong Song
Journal: Journal of Clinical Oncology (2017)

e13120 Background: The ROS1 rearrangement has been identified in 1%-2% of NSCLC cases, these patients would benefit from the inhibitor of crizotinib. But the resistance to crizotinib inevitably developed in the patients with ROS1+ NSCLC and shown a response to crizotinib initially. The mechanism of acquired resistance to crizotinib for the patients with ROS1+ NSCLC is not identified completely now. In this study, we performed mutational profiling in a cohort of 16 ROS1+NSCLC patients at diagnosis and acquired resistance to crizotinib using targeted NGS. Methods: A total of 16 patients with stage IIIb-IV ROS1+ NSCLC were undergoing tumor biopsies or blood withdrawing by the time of acquiring resistance to crizotinib, including 4 formalin-fixed paraffin-embedded (FFPE) samples, 9 serum samples and 3 serous effusions. We used targeted NGS to detect genes status of patients. Results: In total, we identified 62 genetic alterations with a median of 3.9 mutations per patient. 93% of patients still exhibit fusions, and 31% of patients acquired ROS1 required point mutations. Besides other known resistance mechanisms, we identified CDKN2A mutations in 19% of patients. Interestingly, we also observed TERT, PTPRD, NFE2L2 and OR5L2 mutations in ROS1 required point mutations negative patients, which were restricted to crizotinib resistance. Conclusions: Our study uncovered mutational profiles of ROS1+NSCLC patients with crizotinib resistance with potential therapeutic implications, and this study also depicted the genetic landscapes comprehensively in Chinese ROS1+NSCLC population resistant to crizotinib. Our analysis demonstrates new perspectives for further study of resistance and putting forward corresponding relevant tactics against the challenge of disease progression.
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative
Authors: Jasmin B Kuemmerle-Deschner, Sandra Hansmann, Nico M Wulffraat, Sebastiaan J Vastert, Kristien Hens, Jordi Anton, Tadej Avcin, Alberto Martini, Isabelle Koné-Paut, Yosef Uziel, Angelo Ravelli, Carine Wouters, David Shaw, Seza Özen, Andreas Eikelberg, Berent J Prakken, Nicolino Ruperto, Gerd Horneff, Tamas Constantin, Michael W Beresford, Marijn Sikken, Helen E Foster, Iris Haug, Sabrina Schuller, Christine Jägle, Susanne M Benseler
Journal: Annals of the Rheumatic Diseases (2017)

Innovative research in childhood rheumatic diseases mandates international collaborations. However, researchers struggle with significant regulatory heterogeneity; an enabling European Union (EU)-wide framework is missing. The aims of the study were to systematically review the evidence for best practice and to establish recommendations for collaborative research. The Paediatric Rheumatology European Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) project enabled a scoping review and expert discussion, which then informed the systematic literature review. Published evidence was synthesised; recommendations were drafted. An iterative review process and consultations with Ethics Committees and European experts for ethical and legal aspects of paediatric research refined the recommendations. SHARE experts and patient representatives vetted the proposed recommendations at a consensus meeting using Nominal Group Technique. Agreement of 80% was mandatory for inclusion. The systematic literature review returned 1319 records. A total of 223 full-text publications plus 22 international normative documents were reviewed; 85 publications and 16 normative documents were included. A total of 21 recommendations were established including general principles (1-3), ethics (4-7), paediatric principles (8 and 9), consent to paediatric research (10-14), paediatric databank and biobank (15 and 16), sharing of data and samples (17-19), and commercialisation and third parties (20 and 21). The refined recommendations resulted in an agreement of >80% for all recommendations. The SHARE initiative established the first recommendations for Paediatric Rheumatology collaborative research across borders in Europe. These provide strong support for an urgently needed European framework and evidence-based guidance for its implementation. Such changes will promote research in children with rheumatic diseases.
Autoadjusted versus fixed CPAP for obstructive sleep apnoea: a multicentre, randomised equivalence trial
Authors: Konrad E Bloch, Fabienne Huber, Michael Furian, Tsogyal D Latshang, Christian M Lo Cascio, Yvonne Nussbaumer-Ochsner, Oliver Senn, Erich W Russi, Malcolm Kohler, Otto D Schoch, Alexander Turk, Edelbert Imhof, Irène Laube, Felix Matthews, Robert Thurnheer
Journal: Thorax (2017)

Background The obstructive sleep apnoea syndrome (OSAS) is conventionally treated by continuous positive airway pressure set at a fixed level (fCPAP). Automatic mask pressure adjustment (autoCPAP) is increasingly used during home therapy. We investigated whether autoCPAP is equivalent to fCPAP in improving sleepiness in patients with OSAS in the long-term. Methods In this multicentre equivalence trial, 208 patients with OSAS, with median Epworth sleepiness score (ESS) 13, apnoea/hypopnoea index 48.4/hour, were randomised to treatment with autoCPAP (5–15 mbar) or fCPAP (pressure set at the 90th percentile applied by autoCPAP during 2–4 weeks adaptation). Coprimary outcomes were changes in subjective and objective sleepiness from baseline to 2 years after treatment. Equivalence ranges were ±2 points in ESS and ±3 min sleep resistance time evaluated by recording responses to light signals. Results At 2 years, in the intention to treat analysis, the reduction in sleepiness versus pretreatment baseline was similar in patients using autoCPAP (n=113, mean ESS-change −6.3, 95% CI −7.1 to −5.5; sleep resistance time +8.3 min, +6.9 to +9.7) and fCPAP (n=95, mean ESS-change −6.2, 95% CI −7.0 to −5.3; sleep resistance time +6.3 min, +4.7 to +7.8). The 95% CI of difference in ESS-reduction between autoCPAP and fCPAP was −0.9 to +1.4 and the 95% CI of difference in increase in sleep resistance time was −2.6 to +1.0 min. Blood pressure reduction and OSAS-related costs were similar between groups. Conclusions AutoCPAP and fCPAP are equivalent within prespecified ranges in improving subjective and objective sleepiness in patients with OSAS over the course of 2 years. Costs of these treatments are similar. Trial registration number ClinicalTrials.gov NCT00280800 .
Oligonucleotide microarray time-series analysis to evaluate camptothecin effects: A glioblastoma model
Authors: Paola Silingardi, Elena Morandi, Cinzia Severini, Daniele Quercioli, Monica Vaccari, Wolfango Horn, Roberto Serra, Annamaria Colacci
Journal: Cancer Research (2006)

4494   The clinical efficacy of camptothecins, a family of drugs specifically targeting topoisomerase I, is under evaluation for the treatment of malignant gliomas, that are among the most strikingly chemotherapy-unresponsive tumours. Therefore, it is particularly important to understand the molecular mechanisms underlying the response to camptothecin (CPT) in this type of cancer. Agilent’s Oligo 60-mer technology was used to identify genes that are transcriptionally regulated by CPT in two glioma cell line U87-MG and DBTRG-05, during a time-course treatment ranging from 2 to 72 hours. These two models were chosen because of different responses to CPT, as shown by the results obtained from the tests of vitality and apoptosis. We adopted an experimental design consisting of six after-treatment time points compared to an untreated zero-time common reference. Each time point was replicated by performing a dye-swap. To assess differentially expressed genes the transformed data were analysed by MAANOVA (MicroArray ANalysis Of VAriance) data analysis package of R programming environments. We focused on the common mechanisms induced by CPT as well as on the pathways that may explain the substantial variation in the response to the drug in U87-MG and DBTRG cell lines. Moreover, several modulated transcripts were also confirmed by RT-PCR. Many of the genes, that were found to be modulated in both target cells, are specifically involved in regulating cell cycle, DNA repair and /or apoptosis in response to DNA damage, such as cyclin-dependent kinase inhibitor 1A (p21), growth arrest and DNA damage-inducible protein 45 (GADD45), and activating transcription factor 3 (ATF3). Nevertheless, a significantly higher number of down-regulated genes, which are involved in the inhibiton of cell cycle, was found in U87-MG cells. The transcription of other genes such as amphiregulin (AREG), epiregulin (EREG) and MYC, possibly involved in survival signalling in response to genotoxic stress, showed a distinctive regulation depending on the cell line, suggesting a different role of the epidermal growth factor receptor pathway in U87-MG and DBTRG cells.A combination of oligo microarray technology with informatics is a good premise to develop specific drug-gene profiles to be used as molecular markers for potential response to chemotherapy. Supported by the Ministry of Education, University and Research (MIUR), Italy, under grant FISR 1509.
An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia
Authors: Zhisheng Her, Kylie Su Mei Yong, Kathirvel Paramasivam, Wilson Wei Sheng Tan, Xue Ying Chan, Sue Yee Tan, Min Liu, Yong Fan, Yeh Ching Linn, Kam Man Hui, Uttam Surana, Qingfeng Chen
Journal: Journal of Hematology & Oncology (2017)

Xenotransplantation of patient-derived AML (acute myeloid leukemia) cells in NOD-scid Il2rγ null (NSG) mice is the method of choice for evaluating this human hematologic malignancy. However, existing models constructed using intravenous injection in adult or newborn NSG mice have inferior engraftment efficiency, poor peripheral blood engraftment, or are difficult to construct.Here, we describe an improved AML xenograft model where primary human AML cells were injected into NSG newborn pups intrahepatically.Introduction of primary cells from AML patients resulted in high levels of engraftment in peripheral blood, spleen, and bone marrow (BM) of recipient mice. The phenotype of engrafted AML cells remained unaltered during serial transplantation. The mice developed features that are consistent with human AML including spleen enlargement and infiltration of AML cells into multiple organs. Importantly, we demonstrated that although leukemic stem cell activity is enriched and mediated by CD34+CD117+ subpopulation, CD34+CD117- subpopulation can acquire CD34+CD117+ phenotype through de-differentiation. Lastly, we evaluated the therapeutic potential of Sorafenib and Regorafenib in this AML model and found that periphery and spleen AML cells are sensitive to these treatments, whereas BM provides a protective environment to AML.Collectively, our improved model is robust, easy-to-construct, and reliable for pre-clinical AML studies.
Treatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP)
Authors: E. Cortesi, F. Cappuzzo, L. Galli, A. Bearz, S. Pignata, A. Berruti, G. Tortora, D. Tassinari, S. Panni, A. Pazzola, G. Surico, M. Maio, L. Latini, G. Schinzari, V. Adamo, E. Ricevuto, F. Cognetti, U. De Giorgi, G. Cartenì, U. Basso
Journal: Annals of Oncology (2017)
An investigator initiated, open label, randomized, controlled, multicentric study, to assess the safety and efficacy of nimotuzumab (BIOMAb-EGFR) concurrent with cisplatin and radiotherapy (RT) in histologically documented squamous cell carcinoma of the cervix
Authors: B.S. Ajaikumar, K. Swamy, N. Radheshyam, S. Patil, H.P. Shashidhara, M.S.A. Vishweshwara, N.K. Rao, Y. Madhavi, N. Ravi, R. Bilimagga, R. Rao, D. Pawar
Journal: Annals of Oncology (2017)